Carol Nelson, MD
Neurology · Mitchell, SDNPI 1003823410
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,335 of the $59,662 with a category attached, or 87.7%. 18 manufacturers reported payments, led by AbbVie at 52.9% of the total. 2025 is the largest year on record at $50,399, more than ten times the $685 reported in 2019. Among neurology clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $225.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Pfizer$23K
- Johnson & Johnson$4K
- Supernus Pharmaceuticals, Inc.$324
- Teva Pharmaceuticals USA, Inc.$227
- Biohaven Pharmaceuticals, Inc.$159
- plus $370 from 12 others
What the payments were for
- Consulting fees$3,0505%
- Speaking & faculty fees$52,33588%
- Travel & lodging$1,2142%
- Food & beverage$3,0625%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $31,567 |
| Pfizer | 58 | $23,069 |
| Johnson & Johnson | 5 | $3,945 |
| Supernus Pharmaceuticals, Inc. | 47 | $324 |
| Teva Pharmaceuticals USA, Inc. | 34 | $227 |
| Biohaven Pharmaceuticals, Inc. | 4 | $159 |
| AstraZeneca | 5 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Bristol Myers Squibb | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Genentech USA, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $23 |
| Amgen | 1 | $23 |
| Argenx US, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $13 |
| Novartis | 1 | $12 |
| Janssen Scientific Affairs, LLC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$30,411
- NURTEC ODT$22,531
- UBRELVY$20,188
How this compares
$59,662 in reported general payments places this provider in the 90th percentile of 49 neurology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 18 | $19,074 |
| Nurtec OdtRimegepant Sulfate | 14 | $14,669 |
| Ropinirole ErRopinirole Hcl | 15 | $2,577 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 121 | $2,551 |
| Gabapentin | 213 | $1,876 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 63 | $1,833 |
| Propranolol Hcl ErPropranolol Hcl | 27 | $1,522 |
| Levetiracetam | 39 | $1,027 |
| RizatriptanRizatriptan Benzoate | 18 | $557 |
| Venlafaxine Hcl | 12 | $526 |
| Nortriptyline Hcl | 59 | $494 |
| Memantine Hcl | 24 | $483 |
| Sumatriptan Succinate | 18 | $446 |
| Acetazolamide | 13 | $364 |
| Ropinirole Hcl | 19 | $302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta | $31,567 | $19,07418 claims |
| PfizerNurtec Odt | $23,069 | $14,66914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 49 neurology providers in South Dakota.
Other neurology in Mitchell
- Jon GrudemNorth Sioux City$293K
- Andrew RidderSioux Falls$97K
- Wijdan RaiSioux Falls$81K
- Jennifer KrugerRapid City$19K
- Jeffrey BoyleSioux Falls$14K
- Mehwish FarooqiSioux Falls$12K
- Bassel SalemSioux Falls$7K
- Cynthia Zevallos MauSioux Falls$6K
- Mei HeDakota Dunes$5K
- Karan TopiwalaSioux Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.